Search results
Results From The WOW.Com Content Network
Ethambutol enantiomers The antitubercular agent Ethambutol contains two constitutionally symmetrical stereogenic centers in its structure and exists in three stereoisomeric forms. An enantiomeric pair (S,S)- and (R,R)-ethambutol, along with the achiral stereoisomer called meso -form, it holds a diastereomeric relationship with the optically ...
(S,S)-(+)-Ethambutol is powerful and selective antitubercular drug.It is a typical example of an old drug that was introduced for clinical use in its unichiral form. . Ethambutol contains two constitutionally symmetrical chiral centers in its structure and exists in three stereoisomeric forms, the enantiomeric pair (+)-(S,S)- and (−)-(R,R)-ethambutol, along with the achiral stereoisomer called m
An enantiopure drug is a pharmaceutical that is available in one specific enantiomeric form. Most biological molecules (proteins, sugars, etc.) are present in only one of many chiral forms, so different enantiomers of a chiral drug molecule bind differently (or not at all) to target receptors.
A reducing sugar is one that reduces another compound and is itself oxidized; that is, the carbonyl carbon of the sugar is oxidized to a carboxyl group. [2] A sugar is classified as a reducing sugar only if it has an open-chain form with an aldehyde group or a free hemiacetal group. [3]
In these methods, multiple sugars are added to the reaction mixture. One of the sugars is armed as the glycosyl donor, and reacts quickly with a glycosyl acceptor. The non-reducing sugar then acts as a glycosyl acceptor as a protecting group that is easily lost in solution reveals a free hydroxyl group.
Insurance is getting harder to find and more expensive in much of the country. Just ask homeowners' associations. Mirroring trends in the single-family home market, insurers are boosting premiums ...
An oligosaccharide has both a reducing and a non-reducing end. The reducing end of an oligosaccharide is the monosaccharide residue with hemiacetal functionality, thereby capable of reducing the Tollens’ reagent, while the non-reducing end is the monosaccharide residue in acetal form, thus incapable of reducing the Tollens’ reagent. [2]
Companies are racing against the clock this week to notify antitrust agencies about pending deals before a new, more stringent merger filing rule passed during President Joe Biden's administration ...